Drug Trial Radar · NCT00120523
5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Feb 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,418
Actual
Start
Apr 2004
Primary completion
Oct 2010
Study completion Oct 2010
Sponsor
- Lead sponsor
- MEDA Pharma GmbH & Co. KGIndustry
- Sponsor type
- Industry
- First posted
- Jul 18, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 3 months, up to 12 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to investigate the safety of pimecrolimus cream 1% in the long-term treatment (up to 5 years) of atopic dermatitis (eczema) in patients less than 12 months of age compared to topical corticosteroids (TCS).
Conditions
- Atopic Dermatitis
Interventions
PimecrolimusDrug
Pimecrolimus cream 1 %
Topical corticosteroidsDrug
TCS
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Assessed by Adverse EventsTime frame: throughout the 5-year study
- Growth Velocity (Height)Time frame: throughout the 5-year study
- Growth Velocity (Weight)Time frame: throughout the 5-year study
- Potential Effect on the Developing Immune SystemTime frame: throughout the 5-year study
Locations
31 sites in 2 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona
Cholla Pediatrics
Tucson, Arizona
Arkansas Pediatric Clinic
Little Rock, Arkansas
Little Rock Allergy & Asthma Clinic
Little Rock, Arkansas
9540 Artesia Blvd., Suite #1
Bellflower, California
Pediatric Care Medical Group, Inc.
Huntington Beach, California
Longmont Clinical Research
Longmont, Colorado
Children's Skin Center
Miami, Florida
Pediatric Research Center of South Florida
Palm Beach Gardens, Florida
AeroAllergy Research Laboratories of Savanah, Inc.
Savannah, Georgia
The Pediatric Center
Stone Mountain, Georgia
Wayne State University Dermatology
Detroit, Michigan
Michigan State University - Kalamazoo Center for Med Studies
Kalamazoo, Michigan
Respiratory Medicine Research Institute of Michigan
Ypsilanti, Michigan
SMDC Health System
Duluth, Minnesota
Dermatology Center for Children
Minneapolis, Minnesota
University of Minnesota - Dept. of Dermatology
Minneapolis, Minnesota
Radiant Research
Bridgeton, Missouri
Dermatology Associates of Rochester, P.C.
Rochester, New York
Capitol Pediatrics & Adolescent Center
Raleigh, North Carolina
Dermatology Research Associates
Cincinnati, Ohio
Ohio Pediatrics, Inc.
Huber Heights, Ohio
The Portland Clinic
Beaverton, Oregon
Calcagno Research and Development
Gresham, Oregon
Allergy & Asthma Consultants, LLP
Charleston, South Carolina
Allergic Disease and Asthma Center
Greenville, South Carolina
University of Tennessee - Dept. of Pediatrics
Memphis, Tennessee
Suzanne Bruce& Associates, PA
Houston, Texas
Grand Parkway Pediatrics
Sugar Land, Texas
Virginia Commonwealth University
Richmond, Virginia
Novartis
Investigative Site, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.